VGX Inter (KOSPI: 011000) today, "Inovio and affiliates of the United States jointly using technology sinkeon H7N9 bird flu DNA vaccine candidates for preparation of bird flu that is spreading rapidly in China recent pandemik complete derivation was to assess the ability of its prevention during experiments in animal models. "he said.
VGX Inter proceed to Step 1 Universal influenza DNA vaccine development for the prevention of avian flu for DNA vaccine (VGX-3400) for the last 2009 years, last year in the United States, as well as Phase I clinical trials in the country to finish.
VGX Inter through Phase 1 clinical studies for the prevention of the H5N1 bird flu was an excellent ability to prevent the superior safety and a variety of DNA vaccines for the virus subspecies, as well as future H7N9 bird flu DNA vaccine and antigen gene that differ only in the skeleton the same during the clinical development of DNA vaccines that can provide very useful information to shorten the duration of clinical development capabilities were secured.
Inovio and VGX Int. affiliates, jointly by the H7N9 avian influenza outbreaks in domestic pandemic to fast within the time period provided by the DNA vaccine candidates identified prevention capability to conduct a clinical evaluation is ready.
Company officials "for avian influenza prevention DNA vaccine (VGX-3400) Phase 1 clinical finishing, we were H7N9 bird flu DNA vaccine candidate substances derived swine avian flu in the event of a national emergency by the clinical evaluation completed, we proceed." he said.